PainReform Ltd. — FY2020 Form 20-F Summary
Entity and period: The supplied filing is PainReform Ltd.’s annual report for the fiscal year ended December 31, 2020, not a quarterly report. The request metadata names PRF Technologies Ltd.; that name does not match the registrant in the filing. The company is an Israeli clinical-stage pharmaceutical developer, listed on Nasdaq as PRFX, and reports under U.S. GAAP in U.S. dollars. Figures below are U.S. dollars unless stated otherwise.
Business context and financial results
PainReform is developing PRF-110, an extended-release formulation of ropivacaine intended to treat post-operative pain and potentially reduce opioid use. It has no approved products and has never generated revenue. Its small Phase 2 hernia study enrolled 15 patients; the filing reports favorable preliminary findings but notes that the study was not powered to establish statistical significance.
| Metric | FY2020 | FY2019 | Change / context |
|---|---|---|---|
| Revenue | $0 | $0 | No product revenue to date |
| Research and development | $354,000 | $136,000 | Up 160%, primarily in preparation for planned Phase 3 trials |
| General and administrative | $1.317 million | $553,000 | Up 138%, including higher professional fees, D&O insurance and payroll |
| Operating loss | $1.671 million | $689,000 | Loss widened |
| Financial expense, net | $2.162 million | $590,000 | Increase driven mainly by convertible-note costs and warrant fair-value changes |
| Net loss | $4.053 million | $1.279 million | Loss increased 217% |
| Basic and diluted loss per share | $1.25 | $4.17 | Per-share comparison is affected by the substantial increase in weighted-average shares |
Margins are not meaningful because the company had no revenue. FY2020 financial expense included $1.105 million from remeasurement of derivative warrant liabilities; on completion of the IPO, those warrants were reclassified to equity. Thus, the reported net loss includes a significant financing-related fair-value item.
Cash, liquidity and capital
- At December 31, 2020, cash and cash equivalents were $15.677 million, restricted cash was $13,000, and working capital was approximately $16.830 million. Total current assets were $17.791 million and current liabilities were $961,000.
- Operating cash use was $2.557 million in 2020, compared with $609,000 in 2019. Investing cash use was $10,000; financing provided $17.310 million, principally from the September 2020 IPO. Cash, cash equivalents and restricted cash ended the year at $15.690 million.
- All outstanding convertible notes and accrued interest were converted into shares and warrants at the IPO. The year-end balance sheet reported no convertible debt; it reported a $220,000 provision for tax benefits and no derivative warrant liability.
- The company reported an accumulated deficit of $16.481 million and stated that its year-end resources were expected to fund operations and capital requirements for at least 12 months after issuance of the report. This estimate depends on assumptions and is subject to faster-than-expected cash use.
- After year-end, a March 2021 private placement raised $6.0 million gross and approximately $5.5 million net, through shares and accompanying warrants. The company also disclosed $500,000 of placement-agent fees and expenses.
Changes, outlook and principal risks
- Development outlook: Management expected to start the bunionectomy Phase 3 trial by mid-2021, with a hernia-repair Phase 3 trial planned after successful completion of the first. The bunionectomy study design included an initial 15-patient safety and plasma-concentration phase, followed, if criteria were met, by approximately 415 randomized patients. These are plans, not reported trial results or guaranteed timelines.
- Costs and commitments: The company expected losses and expenses to rise as it advanced PRF-110. At December 31, 2020, it disclosed $10.014 million of clinical research and trial agreement obligations, all categorized as due within one year. These include milestone and evaluable-subject payments and should be considered alongside the cash runway statement.
- Capital needs: Management said existing resources were not expected to fund full PRF-110 development and that additional financing would be required. Future equity issuance could dilute shareholders; debt could impose repayment obligations and covenants. The 2021 placement added cash but also warrants and potential dilution.
- Execution and regulatory risks: PRF-110 is the company’s sole lead candidate; it still required Phase 3 trials, regulatory approval and successful commercialization. Trial failure or delay, patient recruitment, manufacturing validation, reliance on third-party manufacturers and the clinical research organization, competition, market acceptance and reimbursement are material uncertainties.
- COVID-19 and operations: The filing said there had been no direct operational impact reported to date, but warned that the pandemic could delay trial initiation and enrollment and disrupt collaborators, suppliers and other vendors. The company also identified Israel-related political and security risks and foreign-exchange exposure.
- Governance and reporting: Management concluded disclosure controls were effective at year-end. The report did not include management’s assessment or auditor attestation of internal control over financial reporting, citing transition and emerging-growth-company exemptions. The independent auditor gave an unqualified opinion on the financial statements, but did not opine on internal-control effectiveness.
- Other items: The company reported no material legal proceedings and no off-balance-sheet arrangements. It stated that it did not expect to pay dividends for the foreseeable future. It believed it was not a PFIC for 2020 but said PFIC status in future years was uncertain.
Most important facts for investors to verify
- Confirm the issuer identity: the filing is for PainReform Ltd., notwithstanding the request metadata’s reference to PRF Technologies Ltd.
- Check whether the planned Phase 3 trials began on schedule, their enrollment and results, and any subsequent regulatory or safety updates.
- Reconcile the $10.014 million of disclosed clinical-trial obligations with cash use, the stated 12-month runway, and subsequent financing.
- Review dilution from the March 2021 placement, outstanding warrants and share options, and the IPO-related securities.
- Assess the components and recurrence of financial expenses, including warrant fair-value movements, and the $220,000 tax provision and uncertain tax position.
- Review subsequent SEC filings for updated cash, spending, financing needs, internal-control findings and any changes to trial or manufacturing plans.